Overview
Switzerland peptide maker's 2025 sales rose 14.8%, beating analyst expectations
EBITDA margin reached 30.9%, with adjusted margin at 28.6% after one-time effects
Company expects 2026 sales growth of 35-45% in local currencies
Outlook
Bachem expects 2026 sales growth of 35%-45% in local currencies
Company sees 2026 EBITDA margin in the low thirties in local currencies
Bachem plans CAPEX investments of more than CHF 400 mln in 2026
Result Drivers
STRONG PRODUCT DEMAND - Co said demand for its products and services remained strong, with a high order situation
PATENT-PROTECTED PEPTIDES - Sales growth in commercial active ingredients was mainly due to higher sales of patent-protected peptides
OPERATIONAL IMPROVEMENTS - Targeted operational improvements increased facility capacity and improved cost structure
Company press release: ID:nNFC2hfJ8h
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Beat
CHF 695.10 mln
CHF 686.81 mln (9 Analysts)
FY Net Income
CHF 148.80 mln
FY EBIT
CHF 167.30 mln
FY EBITDA
CHF 214.70 mln
FY EBITDA Margin
30.90%
FY EBIT Margin
24.10%
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for BACHEM HOLDING AG is CHF76.50, about 39.2% above its March 11 closing price of CHF54.95
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 23 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)